#USA #Westborough #Olympus #Endocision #cryobiopsy

Olympus and Endocision Unite for Advanced Cryobiopsy Technology

Olympus Corporation, a prominent global MedTech enterprise, recently forged a significant global distribution agreement with Endocision. This partnership aims to revolutionize bronchoscopic procedures through the introduction of a novel portable flexible cryocatheter system. Set to launch commercially in the U.S., Canada, and Europe early next year, this collaboration positions both companies at the forefront of respiratory care innovation.

A New Era in Respiratory Solutions

The new cryocatheter system is designed as a single-use, flexible device that does not rely on an electrical power source or large CO2 tanks—a feature that boosts its operational flexibility across a variety of clinical environments. Its portable nature allows utilization in such settings as bronchoscopy suites, emergency departments, and operating rooms, democratizing access to advanced cryobiopsy techniques.

Seiji Kuramoto, Executive Officer at Olympus, emphasized the significance of this agreement, stating, "Our commitment to enhancing respiratory solutions provided by Olympus is illustrated through our collaboration with Endocision. It joins our strong portfolio of products, including endobronchial ultrasound (EBUS), to improve patient outcomes."

Shaping Modern Clinical Practices

This unified approach between Olympus and Endocision signifies a strategic alignment of expertise. Olympus excels in ultrasound technology, while Endocision brings innovative cryotechnology to the table. Their combined efforts aim to broaden diagnostic and therapeutic options within bronchoscopic practices, which are increasingly critical in lung disease management.

Clinical applications of the cryocatheter are varied. It supports transbronchial cryobiopsy for effective tissue acquisition, enables the extraction of foreign objects, blood clots, and mucus plugs, and facilitates tumor debulking and airway recanalization. Recent studies affirm that cryobiopsy techniques yield larger tissue specimens with minimized damage, therefore enhancing the quality of histopathological and molecular analyses compared to traditional biopsy methods.

Access and Versatility for Clinical Environments

Dr. Moishe Liberman, President and Chief Medical Officer of Endocision, expressed enthusiasm about the collaboration: "The Endocision Cryocatheter System is designed to address a broad array of bronchoscopic needs—ranging from effective tissue acquisition to therapeutic interventions—while ensuring that the technology is accessible across various clinical settings."

This agreement underscores a new chapter in minimally invasive procedures in thoracic medicine. With the cryocatheter at the forefront, clinicians can expect enhanced capabilities, leading to better patient outcomes across multiple intervention modalities.

Both companies plan to unveil the Endocision Flexible Cryocatheter System at the upcoming American Association for Bronchology and Interventional Pulmonology (AABIP) conference from August 20-22 in Denver, furthering their commitment to education and innovation in the field.

About Olympus and Endocision

Olympus Corporation boasts a century-long history of focusing on medical technology aimed toward improving patient care and outcomes. With an expansive range of products including ultrasound devices, Olympus partners with healthcare professionals to foster advancements in diagnostics and treatment.

Endocision, a Canadian startup founded in 2019, concentrates on creating cutting-edge cryogenic solutions specifically for lung disease. As the healthcare landscape evolves, collaborations like that of Olympus and Endocision are critical to driving innovation and improving patient care options in the field of interventional pulmonology.